Vector Bioscience develops a machine-learning-driven platform that utilizes metal-organic frameworks (MOFs) as nanoparticles for targeted drug delivery in oncology treatments. This technology enables precise localization of therapeutics, increasing drug uptake while minimizing side effects, addressing the challenge of effective delivery for difficult-to-formulate medications.
Funding
Funding not disclosed
Founders
Product
Problem
Many oncology drugs struggle to reach tumor sites effectively, leading to high systemic toxicity and limited therapeutic impact. Traditional drug delivery methods often fail to achieve sufficient drug concentrations within the tumor microenvironment, especially for difficult-to-formulate medications.
Solution
Vector Bioscience is developing a targeted drug delivery platform using metal-organic frameworks (MOFs) as customizable nanoparticles. These "nanoshuttles" are designed to selectively bind to cancer cells, increasing drug uptake while minimizing off-target effects. The platform employs machine learning to optimize the selection of drug cargoes and tailor the MOF nanoparticles for specific cancer types. This approach enables high local concentrations of therapeutics, even for drugs that are traditionally difficult to formulate, potentially improving treatment outcomes and reducing side effects.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel oncology treatments, as well as clinicians seeking to improve drug delivery efficacy and reduce toxicity in cancer patients.
Features
- Machine-learning-driven selection of drug cargoes and MOF customization for specific cancer types
- Cargo-agnostic technology suitable for a wide range of therapeutic molecules
- Nanoparticle engineering for targeted delivery and enhanced drug loading
- High drug uptake and slow-release kinetics for sustained therapeutic effect
- Data-driven approach to personalize and optimize drug delivery